

# Bio TT<sup>®</sup>

## Tetanus Toxoid Vaccine

### DESCRIPTION

Bio TT<sup>®</sup> is a TT (Tetanus Toxoid) vaccine, containing purified tetanus toxoid adsorbed onto 3 mg/ml aluminum phosphate. Thimerosal 0.1 mg/ml is used as a preservative. One dose of 0.5 ml has a potency of at least 40 IU. Bio TT<sup>®</sup> fulfills WHO requirements for Biological Substances and Indonesian Pharmacopoeia.

### INDICATIONS

For active immunization to produce antibody against tetanus and used in the prevention of neonatal tetanus by immunizing women of child-bearing age.

### PHARMACEUTICAL FORM

Suspension for injection

### COMPOSITION

Each dose (0.5 ml) contains:

Purified tetanus toxoid	10	Lf
Aluminum phosphate (as adsorban)	1.5	mg
Thimerosal (as preservative)	0.05	mg

### ADMINISTRATION

The vaccine should be shaken before use to homogenize the suspension. It should be injected intramuscularly. Sterile needle and a sterile syringe should be used for each injection.

### IMMUNIZATION SCHEDULE

Bio TT<sup>®</sup> immunization for the prevention of tetanus/neonatal tetanus consists of two primary doses of 0.5 ml given intramuscularly at least four weeks apart followed by the third dose at least 6 months later.

To maintain the immunity of women against tetanus through the child-bearing period, a total of five doses are recommended.

A fourth dose should be given at least one year after the third dose, and a fifth dose at least one year after the fourth dose.

Bio TT<sup>®</sup> can be administered safely during pregnancy, preferably after reaching the second trimester. In previously non-immunized women, two doses of Bio TT<sup>®</sup> are recommended in pregnancy, at least 4 weeks apart, the second dose should be given at least two weeks before childbirth, in order to prevent maternal and neonatal tetanus.

Bio TT<sup>®</sup> should also be given in situation where a risk of developing tetanus from any other source exists (e.g. Injuries). At least two doses with at least one month interval will be required to provide basic protection in a previously unimmunized person, and additional booster doses will be required to maintain protection over time. National immunization schedules will provide more details.

Bio TT<sup>®</sup> may be given at the same time as BCG, measles, rubella, mumps, polio (OPV or IPV), hepatitis B, *Haemophilus influenzae type b*, and yellow fever vaccines and vitamin A supplementation.

### SIDE EFFECTS

Rare and mild. Some temporary tenderness and redness at the site of the injection and occasional fever. It is safe to be given during pregnancy.

### CONTRAINDICATIONS

- A severe reaction to previous dose of tetanus toxoid immunization
- Hypersensitive to one of the components in the vaccine
- Should not be given to those having fever or acute infection. Can be administered to those having minor febrile illness such as mild infection on the upper respiration tracks.

### Immune deficiency

Persons infected with human immunodeficiency virus (HIV), whether asymptomatic or symptomatic, should be immunized with Bio TT<sup>®</sup> vaccine according to standard schedules.

### DRUG INTERACTION

Not Reported

### STORAGE

Bio TT<sup>®</sup> should be stored between +2°C and +8°C. DO NOT FREEZE.

### PRESENTATION

Box of 10 ampoules @ 0.5 ml (1 dose)  
Reg. No. DKL0202905843A1

### On Medical Prescription only

01/11/08



Jl. Pasteur no. 28 - Bandung 40161 - Indonesia  
PO Box 1136, Tel. +62 22 2033755, Fax. +62 22 2041306  
www.biofarma.co.id